## Edgar Filing: ACORDA THERAPEUTICS INC - Form 4

ACORDA TH Form 4 March 03, 20	IERAPEUTICS II	NC							
<b>FORM</b> Check this if no longe subject to Section 16 Form 4 or Form 5 obligation may contin <i>See</i> Instruct 1(b).	s box er <b>STATEMH</b> 5. Filed pursu s Section 17(a)	Wa ENT OF CHA ant to Section	ashington, NGES IN I SECUR 16(a) of the Jtility Hold	D.C. 205 BENEFI ITIES e Securiti ling Com	549 CIA es Ez pany	L OW xchang Act o	COMMISSION NERSHIP OF ge Act of 1934, f 1935 or Sectio 40	OMB Number: Expires: Estimated a burden hou response	irs per
(Print or Type R 1. Name and Ac Wasman Jan	dress of Reporting Pe	Symbol	er Name <b>and</b> DA THER R]				5. Relationship of Issuer (Chec	f Reporting Per ck all applicable	
(Mo			3. Date of Earliest Transaction (Month/Day/Year) 03/01/2017				Director 10% Owner XOfficer (give title Other (specify below) President, Intl and GC		
ARDSLEY,		Filed(M	endment, Dat onth/Day/Year) Dle I - Non-D		Securi	ties Ac	<ol> <li>6. Individual or Jo</li> <li>Applicable Line)</li> <li>_X_ Form filed by 0</li> <li> Form filed by N</li> <li>Person</li> </ol>	One Reporting Pe More than One Re	erson eporting
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed	3. f Transactio Code r) (Instr. 8)	4. Securi onAcquirec Disposec (Instr. 3, Amount	ties l (A) c l of (D	or ))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	-
Common Stock	03/01/2017		А	5,000 (1)	А	\$0	106,674	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day/	ate	7. Title and 2 Underlying 9 (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 27.475	03/01/2017		A	12,500	(2)	03/01/2027	Common Stock	12,500

## Edgar Filing: ACORDA THERAPEUTICS INC - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
reporting officer runner runn ous	Director	10% Owner	Officer	Other		
Wasman Jane 420 SAW MILL RIVER ROAD ARDSLEY, NY 10502			President, Intl and GC			
Signatures						

/s/ Jane Wasman	03/03/2017
	00/00/201/

<u>\*\*</u>Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2017, December 1, 2018, December 1, 2019 and December 1, 2020.
- (2) The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2017 with the first quarterly installment vesting on April 1, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.